SOURCE: Imagin Medical Inc.

Imagin Medical Inc.

May 05, 2016 03:05 ET

Imagin Medical Attending American Urological Association Annual Meeting

Imagin Medical is the Developer of the Ultrasensitive i/Blue Imaging System That Will Establish a New Standard of Care for Urologists in Detecting Bladder Cancer Through Endoscopes

VANCOUVER, BC and BOSTON, MA--(Marketwired - May 05, 2016) - Imagin Medical (CSE: IME)(OTC PINK: IMEXF) (the "Company") announced that President and CEO, Jim Hutchens, will be attending the 2016 AUA Annual Meeting held in San Diego, CA, May 6-10.

Mr. Hutchens will be meeting with medical and technical specialists, including Dr. Ralph deVere White, Chairman of Imagin's Scientific Medical Advisory Board and a speaker at the conference, and other key opinion leaders, as well as companies with potential to partner with Imagin. He will also be available during the conference for one-on-one meetings. Conference participants who are interested in meeting with Mr. Hutchens may contact him via the Company website.

About 2016 American Urological Annual Meeting

Urology professionals from around the world will come together in San Diego, CA for the 2016 AUA Annual Meeting. Now in its 111th year, the AUA Annual Meeting is the largest gathering of urologists in the world, providing unparalleled access to groundbreaking research, new guidelines and the latest advances in urologic medicine to positively impact their practices.

AUA has stood at the forefront in developing innovative, evidence-based quality education for urologists and urologic health care professionals worldwide. Through the Annual Meeting -- and other year-round educational offerings -- the AUA sets the highest standards for urologic education worldwide.

About Imagin Medical

Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com.

ON BEHALF OF THE BOARD:

Jim Hutchens,

President & CEO

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Contact Information

  • For further information, contact:
    Bill Galine
    Investor Relations
    Telephone: (775) 737-3292
    Email: billgaline@gmail.com

    890 West Pender Street, Suite 600
    Vancouver, British Columbia
    Canada, V6C 1J9 
    778-998-5000

    133 Hampshire Road
    Wellesley, MA, 02481, USA
    617-571-6006 
    www.imaginmedical.com